144 related articles for article (PubMed ID: 25532817)
1. Upregulation of osteoprotegerin expression correlates with bone invasion and predicts poor clinical outcome in oral cancer.
Russmueller G; Moser D; Würger T; Wrba F; Christopoulos P; Kostakis G; Seemann R; Stadler V; Wimmer G; Kornek G; Psyrri A; Filipits M; Perisanidis C
Oral Oncol; 2015 Mar; 51(3):247-53. PubMed ID: 25532817
[TBL] [Abstract][Full Text] [Related]
2. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
3. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
[TBL] [Abstract][Full Text] [Related]
4. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
5. The RANKL/RANK system as a therapeutic target for bone invasion by oral squamous cell carcinoma (Review).
Jimi E; Shin M; Furuta H; Tada Y; Kusukawa J
Int J Oncol; 2013 Mar; 42(3):803-9. PubMed ID: 23354319
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of RANKL, RANK, and OPG in human oral squamous cell carcinoma.
Chuang FH; Hsue SS; Wu CW; Chen YK
J Oral Pathol Med; 2009 Nov; 38(10):753-8. PubMed ID: 19566744
[TBL] [Abstract][Full Text] [Related]
7. Molecular pathways involved in crosstalk between cancer cells, osteoblasts and osteoclasts in the invasion of bone by oral squamous cell carcinoma.
Quan J; Zhou C; Johnson NW; Francis G; Dahlstrom JE; Gao J
Pathology; 2012 Apr; 44(3):221-7. PubMed ID: 22406484
[TBL] [Abstract][Full Text] [Related]
8. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
[TBL] [Abstract][Full Text] [Related]
9. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis.
Li X; Liu Y; Wu B; Dong Z; Wang Y; Lu J; Shi P; Bai W; Wang Z
Oncol Rep; 2014 Dec; 32(6):2605-11. PubMed ID: 25333856
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of cortical mandibular bone in patients with oral squamous cell carcinoma.
Rabelo GD; Coutinho-Camillo C; Kowalski LP; Portero-Muzy N; Roux JP; Chavassieux P; Alves FA
Clin Oral Investig; 2018 Mar; 22(2):783-790. PubMed ID: 28647863
[TBL] [Abstract][Full Text] [Related]
11. Cancer-associated fibroblasts promote bone invasion in oral squamous cell carcinoma.
Elmusrati AA; Pilborough AE; Khurram SA; Lambert DW
Br J Cancer; 2017 Sep; 117(6):867-875. PubMed ID: 28742795
[TBL] [Abstract][Full Text] [Related]
12. Autoregulation of RANK ligand in oral squamous cell carcinoma tumor cells.
Sambandam Y; Ethiraj P; Hathaway-Schrader JD; Novince CM; Panneerselvam E; Sundaram K; Reddy SV
J Cell Physiol; 2018 Aug; 233(8):6125-6134. PubMed ID: 29323724
[TBL] [Abstract][Full Text] [Related]
13. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor-II mRNA binding protein-3 and podoplanin expression are associated with bone invasion and prognosis in oral squamous cell carcinoma.
Hwang YS; Ahn SY; Moon S; Zheng Z; Cha IH; Kim J; Zhang X
Arch Oral Biol; 2016 Sep; 69():25-32. PubMed ID: 27232357
[TBL] [Abstract][Full Text] [Related]
15. Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy.
Todenhöfer T; Hennenlotter J; Leidenberger P; Wald A; Hohneder A; Kühs U; Mischinger J; Aufderklamm S; Gakis G; Blumenstock G; Stenzl A; Schwentner C
BJU Int; 2014 Jan; 113(1):152-9. PubMed ID: 23360112
[TBL] [Abstract][Full Text] [Related]
16. Prognostics of Cyclin-D1 expression with chemoradiation response in patients of locally advanced oral squamous cell carcinoma.
Khan H; Gupta S; Husain N; Misra S; Singh N; Negi MP
J Cancer Res Ther; 2014; 10(2):258-64. PubMed ID: 25022375
[TBL] [Abstract][Full Text] [Related]
17. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
18. Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657).
Vidula N; Yau C; Li J; Esserman LJ; Rugo HS
Breast Cancer Res Treat; 2017 Aug; 165(1):129-138. PubMed ID: 28577080
[TBL] [Abstract][Full Text] [Related]
19. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
Cross SS; Harrison RF; Balasubramanian SP; Lippitt JM; Evans CA; Reed MW; Holen I
J Clin Pathol; 2006 Jul; 59(7):716-20. PubMed ID: 16489180
[TBL] [Abstract][Full Text] [Related]
20. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.
Van Poznak C; Cross SS; Saggese M; Hudis C; Panageas KS; Norton L; Coleman RE; Holen I
J Clin Pathol; 2006 Jan; 59(1):56-63. PubMed ID: 16394281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
